Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-year booster study of reduced-antigen dTpa vaccine in young adults
2007-003248-31Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of diphtheria, tetanus, and acellular pertussis vaccine (adsorbed, reduced antigen content) in diphtheria, Tetanus and pertussis (2 arms), sponsored by GSK. Primary endpoints: Seroprotection against diphtheria one month after booster and Seroprotection against tetanus one month after booster. Started Oct 2007; status: completed.
02
Drugs
diphtheria, tetanus, and acellular pertussis vaccine (adsorbed, reduced antigen content)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on 2007-003248-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003248-31.